X ylazine is a potent α 2 -adrenergic agonist that induces sedation, analgesia, and muscle relaxation in dogs (Hazra et al., 2008).These characteristics can facilitate different diagnostic procedures and partly optimize canine general anesthesia. Virtually, α 2 -agonists are key factors in achieving smooth induction of anesthesia, reducing requirements of different anesthetics, and improving intraoperative stability (Tranquilli and Maze,1993; Paddl-eford and Harvey,1999;Sinclair, 2003). Despite of this, administration of α 2 -agonists could be complicated with negative cardiovascular effects like bradycardia, cardiac arrhythmias, reduction in cardiac output, and an increase in systemic vascular resistance (Sinclair, 2003;Yaygingül and Belge, 2018). Reduction in breathing rate, hyperglycemia, decreased hematocrit, and vomiting are other adverse events (Ambrisko and Hikasa, 2002;Lemke, 2004;Santos et al., 2006;Baldo et al., 2012). In different animal species, the side effects of α 2 -agonists were described to